Intravitreal Bevacizumab as an adjunct to laser in the management of adult onset Coats’ disease

Goel, Neha; Kumar, Vinod

doi:10.1007/s00417-016-3390-2

Cited by 2 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on previous literature reports, we selected intravitreal injection of anti-VEGF agents as an initial treatment [ 9 , 10 ]. The treatment with the anti-VEGF agent, bevacizumab, was reported in a majority of Coats’ disease [ 7 , 8 ], while the usage of ranibizumab in Coats’ disease was rarely reported. Yang et al analyzed 17 young patients of Coats’ disease and found intravitreal ranibizumab combined with laser and cryotherapies was an effective and a safe treatment approach for Coats’ disease that may improve the visual acuity and reduce the subretinal fluid, exudates, and telangiectasia ([ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, a maximum number of studies continued to use bevacizumab, which is off-label and may have safety concerns [7, 8]. …”

Section: Introductionmentioning

confidence: 99%

“…In recent years, intravitreal anti-vascular endothelial growth factor (VEGF) agents have been reported to reduce the SRF and exudation in Coats’ disease, both alone and in combination with conventional treatment modalities. However, a maximum number of studies continued to use bevacizumab, which is off-label and may have safety concerns [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease

Zhang

Wang

et al. 2018

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

PurposeThe current treatment approaches for Coats’ disease by intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab or conbercept) combined with laser therapy were evaluated for the efficacy during the treatment.MethodsThe medical records of 28 patients diagnosed with Coats’ disease followed by the treatment with intravitreal injection of anti-VEGF agents and laser therapies at Tianjin Medical University Eye Hospital and Hebei Eye Hospital during July 2012 and October 2017 were reviewed retrospectively. Clinical outcomes were recorded with a minimum follow-up of 6 months. The patients were divided into ranibizumab- and conbercept-treated groups, as well as based on age: pediatric and adult groups.ResultTwenty-eight patients were involved in this study. The average number of the injections was 2.82 ± 0.98. Laser photocoagulation was conducted in all patients, and the average number of lasers was 2.63 ± 0.74. The average follow-up period was 24.29 ± 9.85 months. Fourteen patients (50%) were stable, 12 (43%) patients were improved, and 2 patients (7%) showed recurred subretinal fluid and exudation. The final best corrected visual acuity (BCVA) increased markedly after intravitreal injection of ranibizumab or conbercept combined with laser therapy (p = 0.029, p = 0.009, respectively). The number of injections and lasers between conbercept and ranibizumab groups did not vary significantly (p = 0.160, p = 0.573, respectively). Nine patients (60%) in the ranibizumab-treated group and five (38%) in the conbercept-treated group reached a stable phase, and five (33%) and seven (54%) patients got the vision improved after treated with ranibizumab or conbercept, respectively. In pediatric and adult groups, the initial and final BCVA differed significantly (p = 0.03, p = 0.008, respectively). However, the injection number was remarkably different (p = 0.02), while the laser numbers did not have any markedly difference (p = 0.38).ConclusionIntravitreal injection of ranibizumab or conbercept combined with laser therapy is an effective therapeutic option in Coats’ disease. Moreover, the intravitreal injection of ranibizumab or conbercept had no significant adverse effects and appeared to offer visual improvement in Coats’ disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, a maximum number of studies continued to use bevacizumab, which is off-label and may have safety concerns [7, 8]. …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease

Zhang

Wang

et al. 2018

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The use of intravitreal anti-vascular endothelial growth factor (VEGF) agents in combination with common treatments, such as laser photocoagulation, has been reported to reduce the subretinal fluid (SRF) and exudation in small case series of Coats disease (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease

et al. 2021

View full text Add to dashboard Cite

The aim of this retrospective study was to describe the vascular features in eyes with Coats disease, using optical coherence tomography angiography (OCTA), at baseline and after 3 monthly intravitreal injections of ranibizumab. Fifteen eyes of 15 consecutive patients affected by Coats' disease were recruited in this study. All patients underwent the best-corrected visual acuity (BCVA) evaluation, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), multicolor imaging, structural Spectral Domain (SD)-OCT and OCTA at baseline and 1 month after the third monthly ranibizumab injection (loading phase). Fifteen patients completed the study, of whom nine were males and six females. Mean age was 20.4 ± 2 years. BCVA was 0.46 ± 0.11 logMar and 0.47 ± 0.12 logMar at baseline and after treatment, respectively (p = 0.164). SD-OCT revealed no significant decrease in central macular thickness (486.33 μm ± 93.37 at baseline vs. 483.4 μm ± 80.97 after treatment; p = 0.915). The subretinal exudates persisted in macular region after intravitreal injections. OCTA showed a general vascular rarefaction in superficial capillary plexus (SCP), deep capillary plexus (DCP), and choriocapillary (CC) that did not change after loading phase. This study showed no functional and vascular improvement following 3 monthly ranibizumab injections. OCTA, non-invasive technique, could be useful during follow up of these patients and provide a better understand of pathogenesis of this disorder.

show abstract

Intravitreal Bevacizumab as an adjunct to laser in the management of adult onset Coats’ disease

Cited by 2 publications

References 4 publications

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease

Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease

Contact Info

Product

Resources

About